Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294218972> ?p ?o ?g. }
- W4294218972 abstract "Objective: To evaluate the efficacy and safety of Zhibitai (ZBT) in the treatment of patients with hyperlipidemia (HLP). Methods: A search of 8 electronic databases was conducted to find randomized controlled trials (RCTs), to evaluate the efficacy and safety of ZBT for the treatment of HLP. The risk of bias in randomized controlled trials was assessed by using the Cochrane Collaboration Risk of Bias tool for randomized controlled trials 2.0 (RoB 2.0). The primary outcomes were the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). The total effective rate served as the secondary outcome. The incidence of adverse events was considered the safety outcome. Review Manager 5.4 was used to conduct meta-analyses. Data were pooled by random-effects or fixed-effects model to obtain the mean difference (MD), risk ratio (RR), odds ratio (OR), and 95% confidence interval (CI). Results: There were 28 eligible RCTs with a total of 2,952 participants. Overall, we verified that ZBT plus conventional therapy (CT) was superior to CT for the treatment of HLP [TC: MD = -0.50, 95% CI (-0.80, -0.19); TG: MD = -0.38, 95% CI (-0.49, -0.27); LDL-C: MD = -0.50, 95% CI (-0.69, -0.31); HDL-C: MD = 0.17, 95% CI (0.11, 0.24); total effective rate: OR = 4.26, 95% CI (2.28, 7.95)]. There were no significant differences in the primary outcomes between ZBT alone vs. CT (p > 0.05). For safety, the ZBT group (with CT or alone) outperformed the CT group [ZBT alone: RR = 0.51, 95% CI (0.32, 0.81); ZBT plus CT: RR = 0.51, 95% CI (0.30, 0.89)]. For each outcome, the subgroups and the sensitivity analysis matched the overall results. Conclusion: ZBT may be safe and beneficial to HLP patients, especially for serum lipid management. ZBT can be used along with CT for the treatment of HLP. However, it is necessary to conduct more rigorous RCTs to confirm these findings. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022316251]." @default.
- W4294218972 created "2022-09-02" @default.
- W4294218972 creator A5037160914 @default.
- W4294218972 creator A5037546060 @default.
- W4294218972 creator A5038089702 @default.
- W4294218972 creator A5043706949 @default.
- W4294218972 creator A5051166608 @default.
- W4294218972 creator A5052267876 @default.
- W4294218972 creator A5053902230 @default.
- W4294218972 creator A5066716873 @default.
- W4294218972 creator A5074510141 @default.
- W4294218972 creator A5082975868 @default.
- W4294218972 creator A5087295392 @default.
- W4294218972 date "2022-09-02" @default.
- W4294218972 modified "2023-09-27" @default.
- W4294218972 title "Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis" @default.
- W4294218972 cites W201125586 @default.
- W4294218972 cites W2012263023 @default.
- W4294218972 cites W2019071303 @default.
- W4294218972 cites W2024227479 @default.
- W4294218972 cites W2066281438 @default.
- W4294218972 cites W2098045840 @default.
- W4294218972 cites W2110276772 @default.
- W4294218972 cites W2121568629 @default.
- W4294218972 cites W2125435699 @default.
- W4294218972 cites W2134106696 @default.
- W4294218972 cites W2150849842 @default.
- W4294218972 cites W2164089346 @default.
- W4294218972 cites W2196906371 @default.
- W4294218972 cites W2395934013 @default.
- W4294218972 cites W2414916075 @default.
- W4294218972 cites W2474536315 @default.
- W4294218972 cites W2588426511 @default.
- W4294218972 cites W2621322073 @default.
- W4294218972 cites W2708266792 @default.
- W4294218972 cites W2928116029 @default.
- W4294218972 cites W2944477824 @default.
- W4294218972 cites W2953804067 @default.
- W4294218972 cites W2970684805 @default.
- W4294218972 cites W2981344994 @default.
- W4294218972 cites W2991164783 @default.
- W4294218972 cites W2991205756 @default.
- W4294218972 cites W3007511337 @default.
- W4294218972 cites W3013046865 @default.
- W4294218972 cites W3023517259 @default.
- W4294218972 cites W3030850177 @default.
- W4294218972 cites W3031567003 @default.
- W4294218972 cites W3113100691 @default.
- W4294218972 cites W3118615836 @default.
- W4294218972 cites W3125158701 @default.
- W4294218972 cites W3183857127 @default.
- W4294218972 cites W3195904993 @default.
- W4294218972 cites W3214095592 @default.
- W4294218972 cites W4210242902 @default.
- W4294218972 cites W4214921793 @default.
- W4294218972 cites W4220864735 @default.
- W4294218972 cites W4232459612 @default.
- W4294218972 cites W4236673002 @default.
- W4294218972 cites W4292764144 @default.
- W4294218972 cites W4299129122 @default.
- W4294218972 doi "https://doi.org/10.3389/fphar.2022.974995" @default.
- W4294218972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36120312" @default.
- W4294218972 hasPublicationYear "2022" @default.
- W4294218972 type Work @default.
- W4294218972 citedByCount "0" @default.
- W4294218972 crossrefType "journal-article" @default.
- W4294218972 hasAuthorship W4294218972A5037160914 @default.
- W4294218972 hasAuthorship W4294218972A5037546060 @default.
- W4294218972 hasAuthorship W4294218972A5038089702 @default.
- W4294218972 hasAuthorship W4294218972A5043706949 @default.
- W4294218972 hasAuthorship W4294218972A5051166608 @default.
- W4294218972 hasAuthorship W4294218972A5052267876 @default.
- W4294218972 hasAuthorship W4294218972A5053902230 @default.
- W4294218972 hasAuthorship W4294218972A5066716873 @default.
- W4294218972 hasAuthorship W4294218972A5074510141 @default.
- W4294218972 hasAuthorship W4294218972A5082975868 @default.
- W4294218972 hasAuthorship W4294218972A5087295392 @default.
- W4294218972 hasBestOaLocation W42942189721 @default.
- W4294218972 hasConcept C120665830 @default.
- W4294218972 hasConcept C121332964 @default.
- W4294218972 hasConcept C126322002 @default.
- W4294218972 hasConcept C134018914 @default.
- W4294218972 hasConcept C156957248 @default.
- W4294218972 hasConcept C168563851 @default.
- W4294218972 hasConcept C197934379 @default.
- W4294218972 hasConcept C2776478404 @default.
- W4294218972 hasConcept C2779091943 @default.
- W4294218972 hasConcept C44249647 @default.
- W4294218972 hasConcept C555293320 @default.
- W4294218972 hasConcept C61511704 @default.
- W4294218972 hasConcept C71924100 @default.
- W4294218972 hasConcept C82789193 @default.
- W4294218972 hasConcept C95190672 @default.
- W4294218972 hasConceptScore W4294218972C120665830 @default.
- W4294218972 hasConceptScore W4294218972C121332964 @default.
- W4294218972 hasConceptScore W4294218972C126322002 @default.
- W4294218972 hasConceptScore W4294218972C134018914 @default.
- W4294218972 hasConceptScore W4294218972C156957248 @default.
- W4294218972 hasConceptScore W4294218972C168563851 @default.
- W4294218972 hasConceptScore W4294218972C197934379 @default.